drugset
drugset / Trial / NCT03858075

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

NCT03858075 ↗

Phase 1 Completed 108 enrolled Blueprint Medicines Corporation
RandomizedSequentialQuadruple-blindBasic science

Summary

The main objectives of this study are to assess the safety, tolerability, pharmacokinetics (PK), and food effect of BLU-782 in healthy adult subjects.

Timeline

Start
2019-02-12
Primary completion
2019-09-11
Completion
2019-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject FIDRISERTIB Small molecule — Oral

Indications

No indication recorded.